title: 20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency.
authors.affiliation: Allergy Partners of North Texas Research, Dallas, Texas. Electronic address: drrichwasserman@gmail.com.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Wasserman
authors.affiliation: Allergy Associates of the Palm Beaches, North Palm Beach, Florida.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Stein
authors.affiliation: Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: M Elizabeth M
authors.initials: ME
authors.lastname: Younger
authors.affiliation: Larkin Community Hospital, South Miami, Florida.
authors.forename: Shahnaz
authors.initials: S
authors.lastname: Fatteh
authors.affiliation: Department of Pediatrics and Department of Microbiology, Infectiology and Immunology, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
authors.forename: Elie
authors.initials: E
authors.lastname: Haddad
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D017277:Drug Approval; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007136:Immunoglobulins